Predictive factors for ocular complications caused by anticancer drug S-1

Yamada, Rika; Sotozono, Chie; Nakamura, Takahiro; Nishida, Akihiro; Nakanishi, Shinya; Hirabatake, Masaki; Tsuji, Akihito; Kurimoto, Yasuo

doi:10.1007/s10384-015-0421-1

Cited by 9 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other ocular complications due to S-1 include lacrimal duct obstruction, 8–12 corneal abnormalities, 7,8,11 and conjunctival disorders. 10…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, no study has yet reported conjunctival findings of fluorescein staining among patients administered S-1. However, conjunctivitis associated with S-1 administration 10 is thought to be due to a complex disorder including drug-induced impairment, corneal disorders, meibomian gland dysfunction, and lacrimal obstruction.…”

Section: Discussionmentioning

confidence: 99%

“…6 However, these effects on RNA and DNA are not only restricted to cancerous cells, but also affect normal cells, leading to side effects throughout the body. The ophthalmic adverse effects of S-1 include corneal disorders, 7–9 conjunctival disorders, 10 lacrimal duct obstruction, 8–12 and meibomian glands dysfunction. 7,8 Keratoconjunctival disorders lead to photophobia, irritation, and decreased visual acuity, while lacrimal duct obstruction is characterized by epiphora and discharge.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quantitative Analysis of Changes to Meibomian Gland Morphology Due to S-1 Chemotherapy

Ohtomo

Arita

Shirakawa

et al. 2018

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

PurposeThe aim of this prospective, noncomparative, observational case series was to evaluate changes to meibomian gland morphology in patients undergoing S-1 chemotherapy with the use of noninvasive meibography and analytical software.MethodsPatients aged ≥20 years and undergoing S-1 chemotherapy were included. Ophthalmologic examinations were performed before S-1 administration (Pre) and at 1, 3, and 6 months afterward (1M, 3M, and 6M, respectively). Meibography images were analyzed using analytical software. The ratio of the total meibomian gland area relative to the whole measurement area (meibomian gland area ratio [MGAR]) and the rate of change to the MGAR (MGAR at Pre, 1M, 3M, or 6M)/(MGAR at Pre) × 100 were calculated.ResultsIn total, 28 eyelids of seven men (mean age, 68.9 ± 6.3 years) were studied. The mean MGAR of the upper and lower eyelids significantly decreased at 3M (P = 0.0246 and P = 0.00892, respectively) and 6M (P < 0.0001 and P < 0.0001, respectively). There was a significant negative correlation between the cumulative dose of S-1 and the rate of change to the MGAR of the upper (P < 0.0001, r = −0.77) and lower (P < 0.0001, r = −0.785) eyelids. However, there was no other significant difference.ConclusionsThe meibomian gland area decreased after S-1 administration with significant correlations between the rate of change to the MGAR and the mean cumulative dose of S-1.Translational RelevanceSystemic S-1 administration decreased the MGAR in a dose-dependent manner; thus, clinicians should pay more attention to morphologic changes to the meibomian glands during early treatment with S-1.

show abstract

“…Other ocular complications due to S-1 include lacrimal duct obstruction, 8–12 corneal abnormalities, 7,8,11 and conjunctival disorders. 10…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative Analysis of Changes to Meibomian Gland Morphology Due to S-1 Chemotherapy

Ohtomo

Arita

Shirakawa

et al. 2018

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

show abstract

“…S-1, an oral antineoplastic agent containing the prodrug 5-fluorouracil (5-FU), is a popularly used cancer drug especially in Japan. Ocular complications of 5-FU include superficial punctate keratitis (SPK), sheet-like appearance, epithelial erosion, epithelial crack lines, lacrimal duct blockage, and conjunctivitis have also been reported [4,5]. One of pharmacological compounds of S-1, tegafur, becomes 5-FU when it is metabolized in the blood.…”

Section: Casementioning

confidence: 99%

“…Otherwise, in the ocular surface, 5-FU in the lacrimal fluid may induce damages to corneal epithelial cells and stem cells. In Table 1, we present another drug that may induce corneal disorders [3][4][5][6][7][8][9][10][11].…”

Section: Casementioning

confidence: 99%

Anti-Cancer Drug Nab-Paclitaxel May Exacerbate Corneal Epithelial Disorder

Hosotani¹,

Ishikawa²,

Miyanaga³

et al. 2017

J Clin Case Rep

View full text Add to dashboard Cite

Purpose: To report 2 cases of corneal disorder after cancer treatment with nab paclitaxel. Methods: Retrospective review of 2 cases.Case presentation: Case 1 was a 55-year-old female who presented with blurred vision. She underwent cancer treatment in the form of combination therapy with nab-paclitaxel, trastuzumab and pertuzumab for breast cancer 2 weeks before. An ophthalmoscopic examination showed an atypical corneal epithelium invasion in both eyes. The corneal disorder was resolved following discontinuation of nab-paclitaxel. Case 2 had a pancreatic cancer and she presented with an atypical corneal epithelium invasion in both eyes after treatment with S-1 and gemcitabine hydrochloride. The corneal disorder might be caused by S-1, so S-1 treatment was replaced by nab-paclitaxel. The corneal disorder improved temporarily, but it worsened 3 months after the administration of nab-paclitaxel. Finally, the corneal disorder was resolved following the discontinuation of nab-paclitaxel as well as in case 1. Conclusion:Our 2 cases suggest that cancer treatment including nab-paclitaxel may cause severe corneal disorders. Clinicians should consider the possibility of the corneal disorder being caused by the cancer therapy.

show abstract

Gimeracil/oteracil/tegafur

2017

Reactions Weekly

View full text Add to dashboard Cite

Predictive factors for ocular complications caused by anticancer drug S-1

Abstract: Older patients were at greater risk of S-1-related ocular complications, but these complications were not associated with total administration days or total dose.

Cited by 9 publications

References 20 publications

Quantitative Analysis of Changes to Meibomian Gland Morphology Due to S-1 Chemotherapy

Quantitative Analysis of Changes to Meibomian Gland Morphology Due to S-1 Chemotherapy

Anti-Cancer Drug Nab-Paclitaxel May Exacerbate Corneal Epithelial Disorder

Gimeracil/oteracil/tegafur

Contact Info

Product

Resources

About